

# The Utility of Ambulatory Blood Pressure Monitoring for Diagnosing White Coat Hypertension in Older Adults

Kristi Reynolds<sup>1</sup> · C. Barrett Bowling<sup>2,3</sup> · John J. Sim<sup>4</sup> · Lakshmi Sridharan<sup>5</sup> · Teresa N. Harrison<sup>1</sup> · Daichi Shimbo<sup>5</sup>

Published online: 23 September 2015  
© Springer Science+Business Media New York 2015

**Abstract** The beneficial effect of antihypertensive medication on reducing the risk of cardiovascular disease (CVD) events is supported by data from randomized controlled trials of older adults with hypertension. However, in clinical practice, overtreatment of hypertension in older adults may lead to side effects and an increased risk of falls. The diagnosis and treatment of hypertension is primarily based on blood pressure measurements obtained in the clinic setting. Ambulatory blood pressure monitoring (ABPM) complements clinic blood pressure by measuring blood pressure in the out-of-clinic setting. ABPM can be used to identify white coat hypertension, defined as elevated clinic blood pressure and non-elevated ambulatory blood pressure. White coat hypertension is common in older adults but does not appear to be associated with an increased risk of CVD events among this population. Herein, we review the current literature on ABPM in the diagnoses of white coat hypertension in older adults, including its potential role in preventing overtreatment.

**Keywords** Ambulatory blood pressure · Hypertension · White coat hypertension · Elderly · Aged

## Introduction

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in industrialized nations. As the population ages, the contribution of CVD to total morbidity and mortality will increase [1, 2]. Population-based studies have identified a range of risk factors that contribute to incident CVD events. Hypertension is one of the most common, with a prevalence approaching one fourth to one third of the general population in the USA and is even higher among older adults [3, 4]. Approximately two thirds of adults 60 years and older have hypertension in the USA [4].

To identify patients with hypertension and monitor response to antihypertensive medication, guidelines and

---

This article is part of the Topical Collection on *Prevention of Hypertension: Public Health Challenges*

---

✉ Kristi Reynolds  
Kristi.Reynolds@kp.org

C. Barrett Bowling  
cbbowli@emory.edu

John J. Sim  
John.J.Sim@kp.org

Lakshmi Sridharan  
ls3192@cumc.columbia.edu

Teresa N. Harrison  
Teresa.N.Harrison@kp.org

Daichi Shimbo  
ds2231@cumc.columbia.edu

<sup>1</sup> Department of Research & Evaluation, Kaiser Permanente Southern California, 100 South Los Robles, 2nd Floor, Pasadena, CA 91101, USA

<sup>2</sup> Birmingham/Atlanta Geriatric Research, Education, and Clinical Center, Atlanta VAMC, 1670 Clairmont Road (11B), Decatur, GA 30033, USA

<sup>3</sup> Emory University, 1841 Clifton Road, Atlanta, GA 30329, USA

<sup>4</sup> Kaiser Permanente Los Angeles Medical Center, 4700 Sunset Blvd, Los Angeles, CA 90027, USA

<sup>5</sup> Columbia University Medical Center, 622 West 168th Street, PH 9-310, New York, NY 10032, USA

scientific statements recommend measuring blood pressure in the clinic setting [5, 6]. This recommendation is supported by data demonstrating that elevated clinic blood pressure is associated with increased CVD risk and reduction of risk is associated with the lowering of clinic blood pressure with antihypertensive medication [6]. Notably, it has long been recognized that blood pressure varies by the setting in which it is measured. Consequently, clinic blood pressure may differ substantially from out-of-clinic blood pressure [7].

Ambulatory BP monitoring (ABPM) complements clinic blood pressure by quantifying out-of-office ambulatory blood pressure [8]. ABPM can identify the presence of white coat hypertension, defined as elevated clinic blood pressure but non-elevated blood pressure on ABPM [9]. ABPM can also assess the white coat effect, defined as the difference between clinic blood pressure and ambulatory blood pressure [7, 8]. Compared to younger adults, older adults have a higher prevalence of white coat hypertension and a greater white coat effect [10–12]. Herein, we review the current literature on using ABPM to diagnose white coat hypertension with a particular focus on older adults.

## Methods

MEDLINE was searched through July 2015 using the following key words: “ambulatory blood pressure”, “out-of-office blood pressure”, “elderly”, “aged”, “old”, and “older”. Searches were limited to publications in English. We focused on studies published in the past 3 years including original articles; systematic reviews, meta-analyses, narrative reviews; and hypertension guidelines, scientific statements, and position papers.

## Overview of ABPM

Ambulatory blood pressure monitors are compact, worn on a belt or in a pouch, and connected by a tube to a sphygmomanometer cuff on the upper arm. Commonly worn for 24-h, the monitors are most often configured to obtain automatic readings every 15 to 30 min [7]. At the end of the 24-h recording period, the readings are downloaded onto a computer to process and generate a report. The feasibility of conducting ABPM in older adults has been shown to be comparable to younger adults [13•].

To estimate mean blood pressure for different time periods, readings are averaged over three time intervals: daytime, nighttime, and the full 24-h [7, 8]. Several studies have demonstrated that, independent of mean clinic blood pressures, higher mean ambulatory blood pressures during the daytime, nighttime, and 24-h period are associated with an increased

risk of CVD outcomes [14•, 15–18]. In the published literature, mean systolic/diastolic blood pressure values  $\geq 135/85$ ,  $\geq 120/70$ , and  $\geq 130/80$  mmHg are commonly considered to be “elevated” for mean daytime, nighttime, and 24-h blood pressure, respectively [8].


## Definition of White Coat Hypertension and the White Coat Effect

White coat hypertension is typically defined as having elevated clinic blood pressure without elevated daytime blood pressure or alternatively non-elevated 24-h blood pressure on ABPM in individuals not taking antihypertensive medication [7, 8, 19]. White coat hypertension may also refer to individuals taking antihypertensive medication. However, the preferred terms for this subset of patients is “treated white coat hypertension” or “white coat uncontrolled hypertension.”

Figure 1 shows an example case of a 69-year-old adult with treated white coat hypertension who underwent ABPM after having clinic blood pressure measured. In this treated patient taking antihypertensive medication, clinic blood pressure was elevated, but ambulatory blood pressures at daytime, nighttime, and over 24-h were all normal. To the physician or other caregiver taking care of the patient, the patient appears to have uncontrolled hypertension in the clinic setting. In untreated and treated individuals, ABPM can assess the white coat effect, defined as the difference between mean clinic blood pressure and mean ambulatory blood pressure.

## Other Blood Pressure Phenotypes Assessed Using ABPM

ABPM can identify sustained normotension and sustained hypertension, blood pressure phenotypes associated with the lowest and highest CVD risk, respectively [7, 20]. Sustained normotension is defined as non-elevated clinic and non-elevated ambulatory blood pressure; sustained hypertension is defined as elevated clinic and elevated ambulatory blood pressure. ABPM can also identify masked hypertension, defined as non-elevated clinic blood pressure but elevated ambulatory blood pressure in untreated individuals [21]. In addition, ABPM can assess 24-h blood pressure variability and diurnal blood pressure patterns, including blood pressure dipping [6, 8] and morning surge [22]. Finally, ABPM can be used to assess hypotension and evaluate syncope, vertigo, or dizziness, all conditions that disproportionately affect older adults [8, 10]. The reader is referred to recent excellent reviews on these topics [7, 23–25].



**Fig. 1** Blood pressure data from a treated individual who underwent 24-h ambulatory blood pressure monitoring

### White Coat Hypertension in Older Adults

In a recent systematic review, the prevalence of ABPM-assessed white coat hypertension ranged from 5 to 65 % in individuals not taking antihypertensive medication [14]. Compared to sustained normotension, white coat hypertension in untreated individuals is not associated with an increased risk for CVD outcomes in most studies [9, 26, 27–29]. In the few studies that have found increased CVD risk associated with white coat hypertension [30], mean out-of-clinic blood pressure in the white coat hypertension group was higher than the group with sustained normotension, which may have partially explained the increased CVD risk [30, 31].

In a meta-analysis of population-based studies, Ishikawa et al. [11] found clinic blood pressure increased more steeply with age than ambulatory blood pressure. At younger ages, clinic blood pressure was lower than ambulatory blood pressure, while the reverse is true at older ages. This suggests that the white coat effect is greater in older versus younger adults. In a recent population-based study of African-Americans [32], we found that among individuals with clinic hypertension, the white coat effect for systolic blood pressure was greater for individuals 60 years and older (12 mmHg) versus those younger than 60 years (8 mmHg). Several studies have found that the prevalence of white coat hypertension is also higher among older adults [8, 10]. Therefore, the evidence suggests that white coat hypertension and the white coat effect are common in older adults.

White coat hypertension in older adults is not associated with increased CVD outcomes compared to sustained normotension [26]. In a meta-analysis that used data from the International Database of Ambulatory Blood Pressure in

Relation to Cardiovascular Outcomes (IDACO), the hazard ratio (HR) for CVD events was 1.17 (95 % CI 0.87–1.57) for untreated individuals with white coat hypertension compared to their counterparts with sustained normotension [26]. The results were similar when the sample was stratified by age ( $\geq 60$  vs.  $< 60$  years). The HR for CVD events for untreated individuals with white coat hypertension compared to their counterparts with sustained normotension was 1.09 (95 % CI 0.77–1.55) in those 60 years and older and 1.66 (95 % CI 0.60–4.56) in those less than 60 years. These findings were echoed by a second meta-analysis of individual-level data from four population samples of ABPM [16]. Overall, white coat hypertension is not associated with an increased risk of CVD events in older adults.

### Treated White Coat Hypertension in Older Adults

Treated white coat hypertension is common in older adults. In the IDACO, the prevalence of treated white coat hypertension was 47 % in adults [26]. The prevalence of treated white coat hypertension was 50 % in an ABPM substudy of the Hypertension in the Very Elderly Trial (HYVET) [33], which enrolled individuals older than 80 years with predominantly systolic hypertension. The prevalence of white coat hypertension was lower, approximately 19 %, in an ABPM substudy of the Systolic Hypertension in Europe (Syst-Eur) trial, which enrolled individuals 60 years and older with systolic hypertension [34].

Several studies have also shown that the white coat effect is large in older adults taking antihypertensive medication. In an ABPM substudy of the Hypertension Optimal Treatment

(HOT) trial, the white coat effect was 22 mmHg for systolic blood pressure and 15 mmHg for diastolic blood pressure [35]. In the HYVET ABPM substudy [33••], the white coat effect was 36 mmHg for systolic blood pressure and 12 mmHg for diastolic blood pressure. Further, in the Syst-Eur ABPM substudy [34], the white coat effect was 22 mmHg for systolic blood pressure and 2 mmHg for diastolic blood pressure.

In prior studies of ABPM, treated white coat hypertension was not associated with an increased risk of CVD events, compared with treated sustained normotension [9, 26•]. In a meta-analysis using the IDACO data, the HR for CVD events was 1.09 (95 % CI 0.79–1.52) for treated white coat hypertension, compared to their counterparts with treated sustained normotension [26•]. The results were similar when the sample was stratified by age ( $\geq 60$  vs.  $< 60$  years). The HR for CVD events for treated individuals with white coat hypertension compared to their counterparts with treated sustained normotension was 1.09 (95 % CI 0.70–1.69) in those 60 years and older and 0.66 (95 % CI 0.15–2.98) in those less than 60 years. Therefore, treated white coat hypertension and the white coat effect are common in older adults taking antihypertensive medication, and treated white coat hypertension is not associated with an increased risk of CVD events in older adults.

### The Use of ABPM in Assessing White Coat Hypertension in Older Adults

Experts most commonly recommend ABPM to exclude white coat hypertension in individuals with elevated clinic blood pressure [6, 8, 10, 36–39]. In a recent draft statement from the US Preventive Services Task Force (USPSTF) [36], ABPM was recommended for confirming the diagnosis of hypertension and excluding white coat hypertension. A 2011 Expert Consensus Document on Hypertension in the Elderly by the American College of Cardiology Foundation and the American Heart Association recommended ABPM not only to exclude white coat hypertension in untreated older adults but also to assess blood pressure response to antihypertensive medication [8, 10]. Since 2001, the US Centers for Medicaid and Medicare Services has reimbursed the use of ABPM for suspected white coat hypertension [40]. In our previous study, we found that the percentage of US Medicare beneficiaries 65 years and older with ABPM claims was very low and did not change from 2007 through 2010: 0.10, 0.11, 0.10, and 0.09 % for 2007, 2008, 2009, and 2010, respectively [41••]. Although a diagnosis of white coat hypertension was more common in hypertensive individuals with an ABPM claim versus individuals without an ABPM claim, only 60.1 % of individuals with an ABPM claim had a white coat hypertension diagnosis. Further, 86.9 % of Medicare beneficiaries with an ABPM claim, and 95.2 % of hypertensive Medicare beneficiaries with an ABPM claim were taking antihypertensive

medication. These data suggest that the overall use of ABPM is low in older US adults. Further, among older adults, ABPM is not being used primarily for the diagnosis of white coat hypertension in untreated individuals but rather for assessing for treated white coat hypertension in individuals taking antihypertensive medications. It is unknown whether the use of ABPM for the diagnosis of white coat hypertension will increase after the USPSTF draft statement on ABPM was published [36].

The use of ABPM for identifying treated white coat hypertension and assessing the white coat effect in individuals taking antihypertensive medication is more controversial. This is because of the large body of evidence supporting the cardiovascular benefits of antihypertensive treatment guided by clinic blood pressure. The comparative reduction in CVD events by targeting blood pressure on ABPM versus clinic blood pressure is unknown. A prior randomized trial [42] has shown that titrating antihypertensive medication using diastolic blood pressure from ABPM versus titrating using the clinic blood pressure was associated with greater antihypertensive medication discontinuation and less blood pressure control, but no change in left ventricular mass. However, in this study, the follow-up period was relatively short (i.e., less than a year) and the long-term benefit or harm of using ABPM to guide treatment in individuals with hypertension was not assessed.

### The Use of ABPM to Prevent Overtreatment of Older Adults with Hypertension

CVD risk reduction with antihypertensive medication has been demonstrated among selected older adults with hypertension in randomized controlled trials [39, 43]. However, there may be unintended harm with the risk of overtreatment in this population. Older adults appear more susceptible to lower on treatment blood pressures, which may potentially result in paradoxically greater CVD risk [44]. Observational studies in treated hypertension patients have shown that older adults have greater mortality with lower treated blood pressures [45, 46•]. The ACCORD BP study among an older population (mean age 62 years) demonstrated that lower treated blood pressures had greater adverse events including hyperkalemia and worsening renal function [47]. Older adults with hypertension are also susceptible to adverse side effects associated with antihypertensive medication use including postural hypotension, balance and gait impairment, confusion, and dizziness [10]. Further, many but not all studies have shown that antihypertensive medication use is associated with an increased risk of falls and serious fall injuries among older treated adults with hypertension [48, 49, 50••, 51, 52•, 53]. Falls are a major public health concern for elderly individuals [54]. Among older adults, 85 % of all injury-related hospital admissions are related to falls [51, 55]. One in three individuals older than

65 years of age falls annually, and approximately one half of falls will result in an injury [54, 56, 57]. The high rate of falls and associated increased risk for adverse outcomes has generated an immense interest to prevent falls.

Clinicians primarily use clinic blood pressure to make decisions about whether antihypertensive medication should be initiated or intensified in their treated patients with hypertension. As described above, ambulatory blood pressure is substantially lower than clinic blood pressure in older patients who are not taking or who are taking antihypertensive medication. Therefore, in older adults, reducing clinic blood pressure using antihypertensive medication may lead to even lower ambulatory blood pressure, and a potentially higher risk of the sequelae of overtreatment including side effects and falls. Currently, there is a lack of empiric data on using ABPM in older adults for decision-making regarding the initiation and intensification of antihypertensive medication in order to prevent non-CVD-related sequelae of overtreatment. Given the ability of ABPM to determine out-of-clinic blood pressure, ABPM holds much promise for older adults for the diagnosis and treatment of hypertension. The use of ABPM in older adults in clinical practice may prevent hypertension overtreatment and its adverse sequelae including side effects and an increased risk of falls and fall injuries.

## Conclusions

ABPM complements clinic blood pressure by measuring out-of-clinic blood pressure. Ambulatory blood pressure has a stronger association with CVD events than clinic blood pressure. Among those not taking and those taking antihypertensive medication, older adults have a higher risk of white coat hypertension and have a greater white coat effect, compared to younger adults. Therefore, clinic blood pressure provides a poor estimate of out-of-clinic blood pressure in older adults. In older adults, white coat hypertension and treated white coat hypertension are not associated with an increased risk of CVD events. Reliance on clinic blood pressure for the diagnosis and treatment of hypertension in older adults may lead to overtreatment, which is associated with important adverse sequelae. Therefore, ABPM holds great promise for preventing overtreatment and its associated sequelae in older adults with hypertension.

## Compliance with Ethics Guidelines

**Conflict of Interest** Drs. Reynolds, Bowling, Sim, Sridharan, Harrison, and Shimbo declare no conflicts of interest.

**Human and Animal Rights and Informed Consent** This article does not contain any studies with human or animal subjects performed by any of the authors.

**Funding Sources** This work was partially supported by the National Institutes of Health (K24-HL125704) from the National Heart, Lung, and Blood Institute, Bethesda, MD. The funding source had no role in the study design, collection, analysis, interpretation, or drafting of the manuscript or in the decision to submit the manuscript for publication.

## References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Fuster V. Cardiovascular disease in the elderly: a challenge for science and clinical care. *Nat Clin Pract Cardiovasc Med*. 2005;2(11):549.
2. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation*. 2001;104(22):2746–53.
3. Lawes CM, Vander Hoom S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. *Lancet*. 2008;371(9623):1513–8.
4. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. *Hypertension*. 2007;49(1):69–75.
5. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. *Circulation*. 2005;111(5):697–716.
6. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2013;34(28):2159–219.
7. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. *N Engl J Med*. 2006;354(22):2368–74.
8. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. *J Hypertens*. 2013;31(9):1731–68.
9. Franklin SS, Thijs L, Hansen TW, O'Brien E, Staessen JA. White-coat hypertension: new insights from recent studies. *Hypertension*. 2013;62(6):982–7.
10. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. *JACC*. 2011;57(20):2037–114.
11. Ishikawa J, Ishikawa Y, Edmondson D, Pickering TG, Schwartz JE. Age and the difference between awake ambulatory blood pressure and office blood pressure: a meta-analysis. *Blood Press Monit*. 2011;16(4):159–67.
12. Stergiou GS, Ntineri A, Kollias A. Changing relationship among office, ambulatory, and home blood pressure with increasing age: a neglected issue. *Hypertension*. 2014;64(5):931–2.

13. Nesti N, Pieraccioni M, Mossello E, et al. Tolerability of ambulatory blood pressure monitoring (ABPM) in cognitively impaired elderly. *Blood Press*. 2014;23(6):377–80. **This study demonstrated that ABPM was generally tolerated among 176 cognitively impaired patients aged 65 years and older. Only 16% of patients wore the device less than 24 hours and the number of valid ABPM measurements was still close to the minimum required.**
14. Piper MA, Evans CV, Burda BU, Margolis KL, O'Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: an updated systematic review for the U.S. Preventive Services Task Force. *Annals Intern Med*. 2015;162(3):192–204. **This systematic review found that repeated blood pressure measurements may improve the diagnostic accuracy of office blood pressure measurement. Further, that initially elevated office blood pressure should be confirmed by ambulatory blood pressure monitoring to avoid overdiagnosis of isolated clinic hypertension.**
15. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. *Hypertension*. 2008;51(1):55–61.
16. Hansen TW, Kikuya M, Thijs L, et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. *J Hypertens*. 2007;25(8):1554–64.
17. Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. *Lancet*. 2007;370(9594):1219–29.
18. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. *J Hypertens*. 2012;30(3):449–56.
19. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? *JAMA*. 1988;259(2):225–8.
20. Pickering TG, Gerin W, Schwartz JE, Spruill TM, Davidson KW. Franz Volhard lecture: should doctors still measure blood pressure? The missing patients with masked hypertension. *J Hypertens*. 2008;26(12):2259–67.
21. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. *Hypertension*. 2002;40(6):795–6.
22. Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. *Hypertension*. 2010;56(5):765–73.
23. Peacock J, Diaz KM, Viera AJ, Schwartz J, Shimbo D. Unmasking masked hypertension: prevalence, clinical implications, diagnosis, correlates, and future directions. *J Hum Hypertens*. 2014;28(9):521–8.
24. Turner JR, Viera AJ, Shimbo D. Ambulatory blood pressure monitoring in clinical practice: a review. *Am J Med*. 2015;128(1):14–20.
25. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. *Circ Res*. 2015;116(6):1034–45.
26. Franklin SS, Thijs L, Hansen TW, et al. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in relation to cardiovascular outcomes population. *Hypertension*. 2012;59(3):564–71. **This meta-analysis included individuals from the 11-country IDACO population database. Cardiovascular risk in untreated individuals with white-coat hypertension was similar to the risk in untreated normotensive individuals.**
27. Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshida S, Pickering TG. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. *JACC*. 2001;38(1):238–45.
28. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta-analysis. *Am J Hypertens*. 2011;24(1):52–8.
29. Verdecchia P, Reboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat hypertension. *Hypertension*. 2005;45(2):203–8.
30. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. *Hypertension*. 2006;47(5):846–53.
31. Zanchetti A, Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management—is nice always good? *J Hypertens*. 2012;30(4):660–8.
32. Tanner RM, Shimbo D, Seals SR, et al. White-coat effect among older adults: data from the Jackson Heart Study. *J Clin Hypertens*. 2015. doi:10.1111/jch.12644. **Data from 257 participants in the Jackson Heart Study with elevated clinic blood pressure underwent ambulatory blood pressure monitoring. Clinic systolic blood pressure was higher than daytime out-of-clinic blood pressure and this white-coat effect was larger for participants 60 years and older vs. participants less than 60 years of age.**
33. Bulpitt CJ, Beckett N, Peters R, et al. Does white coat hypertension require treatment over age 80?: Results of the hypertension in the very elderly trial ambulatory blood pressure side project. *Hypertension*. 2013;61(1):89–94. **These findings from this study suggest that a systolic blood pressure  $\geq 125$  mmHg on 24-h ambulatory blood pressure monitoring may require treatment in adults older than 80 years.**
34. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. *JAMA*. 1999;282(6):539–46.
35. Mancia G, Omboni S, Parati G, et al. Twenty-four hour ambulatory blood pressure in the hypertension optimal treatment (HOT) study. *J Hypertens*. 2001;19(10):1755–63.
36. Draft Recommendation Statement. Hypertension in Adults: Screening. 2014; <http://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement17/hypertension-in-adults-screening-and-home-monitoring>. Accessed July 5, 2015.
37. Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Can J Cardiol*. 2014;30(5):485–501.
38. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Guideline Development G. Management of hypertension: summary of NICE guidance. *BMJ*. 2011;343:d4891.
39. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. *J Hypertens*. 2014;32(1):3–15.
40. Tunis S, Kendall P, Londner M, Whyte J. Decision Memo for Ambulatory Blood Pressure Monitoring (CAG-00067N). 2001; [http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=5&NcaName=Ambulatory+Blood+Pressure+Monitoring&ver=9&from=%252527Imrpstate%252527&contractor=22&name=CIGNA+Government+Services+\(05535\)+Carrier&letter\\_range=4&bc=gCAAAAAAIAAA&](http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=5&NcaName=Ambulatory+Blood+Pressure+Monitoring&ver=9&from=%252527Imrpstate%252527&contractor=22&name=CIGNA+Government+Services+(05535)+Carrier&letter_range=4&bc=gCAAAAAAIAAA&). Accessed January 14, 2015.
41. Shimbo D, Kent ST, Diaz KM, et al. The use of ambulatory blood pressure monitoring among Medicare beneficiaries in 2007–2010. *J Am Soc Hypertens*. 2014;8(12):891–7. **This study demonstrated that ambulatory blood pressure monitoring use among Medicare beneficiaries between 2007 and 2010 was very low**

- in the USA, and it was not being used to diagnose white coat hypertension.**
42. Staessen JA, Byttebier G, Buntinx F, Celis H, O'Brien ET, Fagard R. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. *JAMA*. 1997;278(13):1065–72.
  43. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311(5):507–20.
  44. Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. *Eur Heart J*. 2010;31(23):2897–908.
  45. Kovesdy CP, Bleyer AJ, Molnar MZ, et al. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. *Annals Intern Med*. 2013;159(4):233–42.
  46. Sim JJ, Shi J, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. *JACC*. 2014;64(6):588–97. **This retrospective study of nearly 400,000 treated hypertensive patients found that patients with systolic and diastolic blood pressures in the ranges of 130–139 mmHg and 60–79 mmHg, respectively, had the lowest risk for mortality and end-stage renal disease.**
  47. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med*. 2010;362(17):1575–85.
  48. Berry SD, Zhu Y, Choi H, Kiel DP, Zhang Y. Diuretic initiation and the acute risk of hip fracture. *Osteoporos Int*. 2013;24(2):689–95.
  49. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. *Arch Intern Med*. 2012;172(22):1739–44.
  50. Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. *JAMA Intern Med*. 2014;174(4):588–95. **During an average follow-up of 3 years in the Medicare Current Beneficiary Survey cohort, 9.0 % of adults aged 70 years and older experienced a serious fall injury. Further, antihypertensive medications were associated with an increased risk of serious fall injuries.**
  51. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. *Arch Intern Med*. 2009;169(21):1952–60.
  52. Margolis KL, Palermo L, Vittinghoff E, et al. Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. *J Gen Intern Med*. 2014;29(12):1599–606. **In a subset of 3,099 participants aged 40–79 years of the Action to Control Cardiovascular Risk in Diabetes randomized trial, intensive antihypertensive treatment that lowered systolic blood pressure to <120 mmHg was not associated with increased risk of falls.**
  53. Peters R, Beckett N, Burch L, et al. The effect of treatment based on a diuretic (indapamide) +/- ACE inhibitor (perindopril) on fractures in the Hypertension in the Very Elderly Trial (HYVET). *Age Ageing*. 2010;39(5):609–16.
  54. Phelan EA, Mahoney JE, Voit JC, Stevens JA. Assessment and management of fall risk in primary care settings. *Med Clin North Am*. 2015;99(2):281–93.
  55. Weir E, Culmer L. Fall prevention in the elderly population. *CMAJ*. 2004;171(7):724.
  56. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. *N Engl J Med*. 1988;319(26):1701–7.
  57. King MB, Tinetti ME. Falls in community-dwelling older persons. *J Am Geriatr Soc*. 1995;43(10):1146–54.